Delivery Order SPE2DB22D2211-SPE2DB25FSDAJ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $31,805.90 to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The contract is scheduled for ultimate completion on June 3, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $35,020.92 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This firm fixed-price delivery order, executed on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $37,967.82 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in packages of 30 units. This delivery order, which is a child contract under a larger vehicle, requires completion by September 4, 2025, and was competitively awarded without set-aside provisions. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $8,727.91 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, scheduled for completion by August 6, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. BIKTARVY is an antiretroviral medication used in HIV treatment,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,116.14 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was issued on September 2, 2025, with an ultimate completion date of September 3, 2025. The contract includes no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance, which aligns with AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $20,672.94 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price contract was executed on April 21, 2025, with an ultimate completion date of April 22, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $4,118.45 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. The delivery was completed by July 23, 2025, and performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This was a competitively awarded contract with no set-aside designation, reflecting the agency's standard procurement practices for pharmaceutical supplies...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $18,825.57 for BIKTARVY 50-200-25 mg tablets (30-count units) on August 20, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026. The place of performance is AmerisourceBergen's Corporate Office...
- The Defense Logistics Agency awarded a $323.8K delivery order to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets in quantities of 30 units, with a completion date of September 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. BIKTARVY is an antiretroviral medication used in HIV treatment, and this delivery...
- The Defense Logistics Agency awarded a $14.4K delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of BIKTARVY 50-200-25 mg tablets (30-count units). The contract is classified as a firm fixed price delivery order with an ultimate completion date of September 17, 2025, and carries no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. BIKTARVY is an...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSDAJDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,644.48 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, competitively awarded on August 18, 2025, with an ultimate completion date of August 19, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999 million and extends through December 2026. As the prime contractor on this comprehensive global pharmaceutical support vehicle, AmerisourceBergen supplies a broad range of pharmaceutical products and medical commodities to support military healthcare programs worldwide. BIKTARVY is an antiretroviral medication used in HIV treatment, reflecting the company's role in delivering specialized pharmaceutical products across multiple therapeutic domains to the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.6k | 8/18/25 |